CAR-T Cell Therapy Market, By Drug Type (Ciloleucel, Axicabtagene, Brexucabtagene Autoleucel, Tisagenlecleucel, and Others), By Indication (Acute Lymphocyctic Leukemia, Lymphoma, Non-Hodgkin Leukemia and Others), By End-Users (Hospitals, Cancer Research Centers, and Others), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2034

Report Code: PMI1918 | Publish Date: April 2024 | No. of Pages: 180

Global CART Cell Therapy Market Overview

Introduction:

CAR-T Cell Therapy   Market was valued at US$ 2.7 Billion in 2024 and is projected to grow at a CAGR of 1.80% to reach US$ 8.7 Billion by 2034.

CAR-T (chimeric antigen receptor) Cell Therapy is a type of treatment where patient’s T cells are changed in laboratory to bind to cancer cells to kill them. CAR-T Cell Therapy has become a new type of cancer treatment where healthcare professionals change T-cells in the lab and then insert into cancer patient to find and destroy cancer cells.

New product launch and approval by FDA (Food and Drug Administration) has given positive impact on target market growth. Growing prevalence of cancer disease has become major contribution in CAR-T Cell Therapy market growth. Further, according to NCI (National Cancer Institute), in 2020, myeloma cancer accounted for around 32,000 (1.8%) cases in United States.

Global CART Cell Therapy Market Dynamics

Growing Prevalence of Cancer Diseases to fuel market growth

Growing prevalence of cancer diseases has given positive impact on target market growth. Unhealthy lifestyle, poor nutrition food, excess use of alcohol, cigarette smoking has given rise in prevalence of cancer diseases which in turn, facilitated the demand for CAR-T Cell Therapy market growth.

For instance, in 2019, according to CDC (Centers for Disease Control and Prevention), around 8,525 new cancer cases of Hodgkin Lymphoma were reported and 943 number of people were died of this cancer in United States. Further, around 50,627 of new cases of leukemia were reported in United States and around 23,337 number of people were died of this type of cancer.

For instance, in 2023, According to data of Government of India it was determined that Jammu & Kashmir has seen a consistent rise in cancer cases with union territory reporting about 51,000 cancer cases in 2019 to 2022. According to study by Sher-e-Kashmir Institute of Medical Sciences (SKIMS) attributed the rising cancer incidence to dietary practices & lifestyle choices and intake of higher salt content foods in Jammu & Kashmir.

                                      Approval of CAR-T Cell Therapies to fuel market growth

Approval of CAR-T cell therapies has fueled the demand for target market growth. US FDA (Food and Drug Administration) has approved CAR-T cell therapies to treat leukemia, multiple myeloma and lymphomas.

According to American Cancer Society, currently approved CAR-T cell therapies are: Axicabtagene (Yescarta), Tisagenlecleucel (Kymriah), Lisocabtagene maraleucel (Breyanzi), Ciltacabtegene autoleucel (Carvykit), Idecabtagene vicleucel (Abecma), and Brexucabtagene autoleucel (Tecartus).

For instance, in March 2022, JW Therapeutics received IND (Investigational Clearance) from NMPA (National Medical Products Administration) of China for its clinical trial of anti-CD19 autologous chimeric antigen receptor T (CAR-T) cell immunotherapy product relmacabtagene autoleucel injection (Carteyva) for treating second-line of large B-Cell lymphoma.

Restrains:

CAR-T cell therapies are effective but can cause some serious and life-threatening side-effects such as trouble in breathing, high fever & chills, headache, joint pain, feeling tired, nausea, vomiting, fast heartbeat has restrained the CAR-T Cell Therapy market growth. Other serious side-effects such as weakened immune system, allergic reactions, low blood cell count, abnormal level of minerals in blood has hampered the demand for CAR-T Cell Therapy market growth.

Access Crucial Insights at a Fraction of the Cost | Request Your Discount

Global CART Cell Therapy Market Segmentation

Segmentation - CAR-T Cell Therapy Market

CAR-T Cell Therapy Market is segmented based on Drug Type, Indication, End-Users and Region.

Drug Type Insight

On the basis of Drug Type, CAR-T Cell Therapy Market is segmented into Ciloleucel, Axicabtagene, Brexucabtagene Autoleucel, Tisagenlecleucel, and Others. Axicabtagene drug type segment is expected to dominate the target market growth due to growing adoption of Axicabtagene (Yescarta) medicine for treating refractory or relapse follicular lymphoma and large B-cell lymphoma.

Indication Insights

On the basis of Indication, CAR-T Cell Therapy Market is segmented into Acute Lymphocyctic Leukemia, Lymphoma, Non-Hodgkin Leukemia and Others. Lymphoma indication segment is expected to dominate the target market growth due to growing number of target population and increasing number of CAR-T cell therapies for treating lymphoma.

End-Users Insights

On the basis of End-Users, CAR-T Cell Therapy Market is segmented into Hospitals, Cancer Research Centers, and Others. Hospitals end-user segment is expected to dominate the target market growth due to growing number of patient admission, robust healthcare infrastructure and availability of all facilities under one roof.

Regional Insights:

On region the CAR-T Cell Therapy Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The North America market is estimated to witness a significantly high revenue share over the forecast period. Moreover, rising prevalence of cancer disease, high economic status, technological advancement, growing adoption of CAR-T Cell therapy, ongoing research and development activities, and presence of major key players is anticipated to increase demand for CAR-T Cell Therapy in the region.

Reduce costs by up to 30% with a custom report tailored to your specific needs | Request Customized Report

Report Scope:

Attribute

Details

Base year for estimation

2023

Forecast period

2024 – 2034

Market representation

Revenue in USD Billion & CAGR from 2024 to 2034

Market Segmentation

By Drug Type - Ciloleucel, Axicabtagene, Brexucabtagene Autoleucel, Tisagenlecleucel, and Others

By Indication - Acute Lymphocyctic Leukemia, Lymphoma, Non-Hodgkin Leukemia and Others

By End-Users - Hospitals, Cancer Research Centers, and Others

Regional scope

North America - U.S., Canada

Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe

Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific

Latin America - Brazil, Mexico, Argentina, Rest of Latin America

Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa

Report coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2022 to 2032. For the purpose of this study, has segmented the CAR-T Cell Therapy Market report based on Drug Type, Indication, End-Users and Region:

CAR-T Cell Therapy Market, By Drug Type:

  • Ciloleucel
  • Axicabtagene
  • Brexucabtagene Autoleucel
  • Tisagenlecleucel
  • Others

CAR-T Cell Therapy Market, By Indication:

  • Acute Lymphocyctic Leukemia
  • Lymphoma
  • Non-Hodgkin Leukemia
  • Others

CAR-T Cell Therapy Market, By End-Users:

  • Hospitals
  • Cancer Research Centers
  • Others

CAR-T Cell Therapy Market, By Region:

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Russia
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • Israel
    • South Africa
    • Rest of Middle East & Africa

Global CART Cell Therapy Market Key Players

The key players operating the CAR-T Cell Therapy Market includes, Bristol Myer Squibb, Merck & Co. Inc., Pfizer Inc., Bluebird Bio-Inc., Novartis AG, Caribou Biosciences Inc., Celgene Corporation, Sorrento Therapeutics Inc., Miltenyi Biotech, Cartesian Therapeutics and others.

Global CART Cell Therapy Market Key Issues Addressed

Recent Development:

  • In April 2023, Novartis signed three year contract for manufacturing “Carvykti” and also will help Legend biotech and Johnson & Johnson in developing clinical batches of CAR-T cell therapy “Carvykti” for treating multiple myeloma disease.
  • In April 2023, Gilead Sciences to grow its position in oncology market and delivered $670- million in oncology sales. Gilead Sciences set to support CAR-T cell therapy “Yescarta”.
  • In April 2023, Johnson & Johnson study data showed dramatic benefits to multiple myeloma cell therapy. The result showed J&J and Legend’s therapy, “Carvykti” in reducing risk of disease progression by more than 70% over standard drugs.
  • In November 2022, AstraZeneca’s move into cell therapy yielded truly novel cancer target and the company set to enter in clinical trials. AstraZeneca’s early oncology clinical trial program revealed the existence of anti-Steap2 Car-T therapy “AZDO754”.

Global CART Cell Therapy Market Company Profile

  • Bristol Myer Squibb*
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
  • Merck & Co. Inc.
  • Pfizer Inc.
  • Bluebird Bio-Inc.
  • Novartis AG
  • Caribou Biosciences Inc.
  • Celgene Corporation
  • Sorrento Therapeutics Inc.
  • Miltenyi Biotech
  • Cartesian Therapeutics

“*” marked represents similar segmentation in other categories in the respective section.

Global CART Cell Therapy Market Table of Contents

  1. Research Objective and Assumption
    • Preface
    • Research Objectives
    • Study Scope
    • Years Considered for the study
    • Assumptions
    • Abbreviations
  2. Research Methodology
    • Research data
    • Primary Data
      • Primary Interviews
      • Primary Breakdown
      • Key data from Primary Sources
      • Key Thickness Insights
    • Secondary Data
      • Major Secondary Sources
      • Secondary Sources
    • Market Estimation
    • Top-Down Approach
      • Approach for estimating Market Share by Top-Down Analysis (Supply Side)
    • Bottom-Up Approach
      • Approach for estimating market share by Bottom-up Analysis (Demand Side)
    • Market Breakdown and Data Triangulation
    • Research Assumptions
  3. Market Preview
    • Executive Summary
    • Key Findings—Global Outlook for medical carts Strategies
      • Key Questions this Study will Answer
      • Market Snippet, By Drug Type
      • Market Snippet, By Indication
      • Market Snippet, By End-Users
      • Market Snippet, By Region
    • Opportunity Map Analysis
    • Executive Summary—3 Big Predictions
  4. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restrains
      • Market Opportunities
      • Market Trends
    • DR Impact Analysis
    • PEST Analysis
    • Porter’s Five Forces Analysis
    • Opportunity Orbit
    • Market Investment Feasibility Index
    • Macroeconomic Factor Analysis
  5. Market Segmentation, By Drug Type
    • Overview
      • Market Value and Forecast (US$ Bn), and Share Analysis (%), 2022 – 2032
      • Y-o-Y Growth Analysis (%), 2022 – 2032
      • Segment Trends
    • Ciloleucel
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
    • Axicabtagene
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
    • Brexucabtagene Autoleucel
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
    • Tisagenlecleucel
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
    • Others
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
  6. Market Segmentation, By Indication, 2022 – 2032, (US$ Bn)
    • Overview                                      
      • Market Value and Forecast (US$ Bn), and Share Analysis (%), 2022 – 2032
      • Y-o-Y Growth Analysis (%), 2022 – 2032
      • Segment Trends
    • Acute Lymphocyctic Leukemia
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
    • Lymphoma
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
    • Non-Hodgkin Leukemia
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
    • Others
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
  7. Market Segmentation, By End-Users, 2022 – 2032, (US$ Bn)
    • Overview                                      
      • Market Value and Forecast (US$ Bn), and Share Analysis (%), 2022 – 2032
      • Y-o-Y Growth Analysis (%), 2022 – 2032
      • Segment Trends
    • Hospitals
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
    • Cancer Research Centers
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
    • Others
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
  8. Global Market, By Region, 2022 – 2032, (US$ Bn)
    • Overview
      • Market Value and Forecast (US$ Bn), and Share Analysis (%), 2022 – 2032
      • Y-o-Y Growth Analysis (%), 2022 – 2032
      • Regional Trends
    • North America
      • Market Size and Forecast (US$ Bn), By Drug Type, 2022 – 2032
      • Market Size and Forecast (US$ Bn), By Indication, 2022 – 2032
      • Market Size and Forecast (US$ Bn), By End-Users, 2022 – 2032
      • Market Size and Forecast (US$ Bn), By Country, 2022 – 2032
        • U.S.
        • Canada
    • Europe
      • Market Size and Forecast (US$ Bn), By Drug Type, 2022 – 2032
      • Market Size and Forecast (US$ Bn), By Indication, 2022 – 2032
      • Market Size and Forecast (US$ Bn), By End-Users, 2022 – 2032
      • Market Size and Forecast (US$ Bn), By Country, 2022 – 2032
        • UK
        • France
        • Germany
        • Russia
        • Italy
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast (US$ Bn), By Drug Type, 2022 – 2032
      • Market Size and Forecast (US$ Bn), By Indication, 2022 – 2032
      • Market Size and Forecast (US$ Bn), By End-Users, 2022 – 2032
      • Market Size and Forecast (US$ Bn), By Country, 2022 – 2032
        • India
        • Japan
        • South Korea
        • China
        • Rest of Asia Pacific
    • Latin America
      • Market Size and Forecast (US$ Bn), By Drug Type, 2022 – 2032
      • Market Size and Forecast (US$ Bn), By Indication, 2022 – 2032
      • Market Size and Forecast (US$ Bn), By End-Users, 2022 – 2032
      • Market Size and Forecast (US$ Bn), By Country, 2022 – 2032
        • Brazil
        • Mexico
        • Rest of Latin America
    • Middle East & Africa
      • Market Size and Forecast (US$ Bn), By Drug Type, 2022 – 2032
      • Market Size and Forecast (US$ Bn), By Indication, 2022 – 2032
      • Market Size and Forecast (US$ Bn), By End-Users, 2022 – 2032
      • Market Size and Forecast (US$ Bn), By Country, 2022 – 2032
        • GCC
        • Israel
        • South Africa
        • Rest of Middle East
  2. Competitive Landscape
    • Heat Map Analysis
    • Market Presence and Specificity Analysis
  3. Company Profiles 
  • Bristol Myer Squibb
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Merck & Co. Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Pfizer Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Bluebird Bio-Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Novartis AG
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Caribou Biosciences Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Celgene Corporation
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Sorrento Therapeutics Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Miltenyi Biotech
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Cartesian Therapeutics
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  1. The Last Word
    • Future Impact
    • About Us
    • Contact

 

FAQs

The global CAR-T cell therapy market has been segmented on the basis of therapeutic application, and region.

Presence of potential CAR-T cell therapies in the pipeline in major players of the biotechnology and biopharmaceutical companies for different indication is expected to augment the growth of CAR-T cell therapy.

Top players involved in Global CAR-T Cell Therapy are Novartis and Kite Pharma, Inc., Juno Therapeutics, Pfizer, Inc., Bellicum Pharmaceuticals, Inc., Celgene Corporation, and Cellectis